Hansa Biopharma to host Q1 2026 interim results conference call

About this update from Hansa Biopharma Ab

Lund, Sweden , 8 April, 2026 . Hansa Biopharma , "Hansa" ( Nasdaq Stockholm : HNSA), will publish its interim report for January - March 2026 on 23 April, 2026 . Interested parties may join the Company's quarterly conference call on the same date at 14:00 CEST /  8:00 AM EDT . The event will be hosted by Renée Aguiar-Lucander , CEO, Evan Ballantyne , CFO, Richard Philipson , CMO, and Maria Törnsén, COO and President U.S. During the call, management will review the Company's interim financial results and provide a business and pipeline update. The presentation will be held in English. Slides used in the presentation will be made available on the company website at the following link: Financial reports | Hansa Biopharma To participate in the telephone conference, please use the dial-in details provided below: Participant Dial In (USA/ Canada Toll Free): 1-833-821-3542 Participant International Dial In: 1-412-652-1248 The webcast will be available on: Webcast | Hansa Biopharma First Quarter 2026 Earnings --- ENDS --- Contacts for more information: Evan Ballantyne , Chief Financial Officer [email protected] Kerstin Falck , VP Global Corporate Affairs [email protected] Notes to editors About Hansa Biopharma Hansa Biopharma AB is a pioneering commercial-stage biopharmaceutical company developing and commercializing novel immunomodulatory therapies to transform care for patients with acute or complex immune disorders. Hansa's proprietary IgG-cleaving enzyme technology platform addresses serious unmet medical needs in transplantation, gene therapy and autoimmune diseases. The company's portfolio includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients, and HNSA-5487, a next-generation IgG-cleaving molecule that will be developed for Guillain-Barré Syndrome (GBS). Hansa Biopharma is based in Lund, Sweden , and has operations in Europe and the U.S. The company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at www.hansabiopharma.com and follow us on LinkedIn. ©2026 Hansa Biopharma AB. Hansa Biopharma , the beacon logo, IDEFIRIX, and IDEFIRIX flower logo are trademarks of Hansa Biopharma AB , Lund, Sweden . All rights reserved. https://news.cision.com/hansa-biopharma-ab/r/hansa-biopharma-to-host-q1-2026-interim-results-conference-call,c4332272 https://mb.cision.com/Main/1219/4332272/4027459.pdf (c) 2026 Cision. All rights reserved., source Press Releases - English

View stock analysis, news, and events for Hansa Biopharma Ab